1 hour ago
HomeMarket NewsAstraZeneca Pharma receives CDSCO nod for cancer treatment drug
AstraZeneca Pharma, in an exchange filing, said it has received the CDSCO's permission to import for sales and distribution of the solution for infusion 120 mg/2.4 ml and 500mg/10 ml for an additional indication.
(Photo Credit :
CNBC-TV18 Library
)
AstraZeneca Pharma India Ltd. on Saturday, January 31, said it has received permission from the Central Drugs Standard Control Organisation (CDSCO) for Imfinzi or durvalumab solution.
The same is indicated for the treatment of adult patients with resectable gastric or gastroesophageal junction adenocarcinoma.
AstraZeneca Pharma, in an exchange filing, said it has received the CDSCO's permission to import for sales and distribution of the solution for infusion 120 mg/2.4 ml and 500mg/10 ml for an additional indication.
With this approval, durvalumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) chemotherapy as neoadjuvant and adjuvant treatment, followed by single-agent durvalumab, is indicated for the treatment of the above mentioned patients, the company said.
The permission paves way for the marketing of the solution for infusion in the two mentioned strengths in India for the specified additional indication, subject to the related statutory approvals, if any, it added.
Shares of AstraZeneca Pharma ended the previous session 1.8% up at ₹8,540 apiece. The stock has 18% in the previous year.
Also Read: Central Bank of India ties up with HSBC AMC to distribute mutual fund products
